Back to top
more

Integra LifeSciences (IART)

(Delayed Data from NSDQ)

$26.98 USD

26.98
1,204,657

-0.56 (-2.03%)

Updated May 20, 2024 04:00 PM ET

After-Market: $26.96 -0.02 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (140 out of 249)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

ResMed (RMD) Q3 Earnings Surpass Estimates, Revenues Miss

Lower device sales including weak demand for ventilators due to COVID-19 hurt ResMed's (RMD) Q3 top line.

Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Guidance Up

Bio-Rad's (BIO) first-quarter revenues improved year over year on robust growth in Life Science and Clinical Diagnostics segments.

Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up

Syneos Health (SYNH) registers sales uptick in its Clinical Solutions business on the back of favorable acquisition impacts and increased project start-up activities.

Integra (IART) Hits Fresh High: Is There Still Room to Run?

Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Integra (IART) Q1 Earnings Beat Estimates, Gross Margin Down

Integra's (IART) first-quarter revenues improved year over year on organic growth across Codman Specialty Surgical and Tissue Technologies segments.

Integra LifeSciences (IART) Q1 Earnings and Revenues Top Estimates

Integra (IART) delivered earnings and revenue surprises of 23.21% and 2.92%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Product Stocks' Earnings on Apr 28: BSX, ALGN & More

The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

ResMed (RMD) to Report Q3 Earnings: What's in the Offing?

Improvement in demand for Mask and Other accessories along with rapid adoption of digital health solution is likely to have contributed to ResMed's (RMD) Q3 growth.

Integra (IART) to Report Q1 Earnings: What's in the Offing?

The acquisition of ACell, and faster recovery growth rate in Japan and China are likely to have helped recover Integra's first-quarter 2021 performance.

Debanjana Dey headshot

Orthopedic Space Gains Momentum in 2021: 5 Stocks in Focus

Here are five orthopedic device stocks, Integra (IART), Conformis (CFMS), SeaSpine (SPNE), Zimmer Biomet (ZBH), Orthofix (OFIX), which are expected to continue their run over the next few months.

Intuitive Surgical (ISRG) Q1 Earnings & Revenues Top Estimates

Intuitive Surgical's (ISRG) first-quarter results reflect strong segmental performance.

Abbott (ABT) Q1 Earnings Miss, Diagnostic Test Sales Solid

Abbott (ABT) reports strong Diagnostics sales for the first quarter driven by growing demand for its BinaxNOW, Panbio and ID NOW rapid testing platforms.

Integra (IART) Hits New 52-Week High: What's Driving It?

Integra (IART) is optimistic about maintaining its strength in its international business, along with its portfolio optimization strategy.

Here's Why You Should Retain Integra LifeSciences (IART) Stock

Investors are optimistic about Integra LifeSciences (IART) stock, owing to its strong international business growth and focus on portfolio optimization.

Integra's (IART) Neurosurgery Rebounds Despite Supply Issues

Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically,

Veeva (VEEV) Partners With Impel, Boosts Cloud-Based Offerings (Revised)

Veeva (VEEV) collaborates with Impel to accelerate the pre-launch planning and digital-first commercial execution for migraine treatment.

Integra (IART) Down 3% Since Last Earnings Report: Can It Rebound?

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Integra (IART) Neurosurgery Grows Sequentially Amid Supply Woe

Most of Integra's (IART) franchises or products succeed in sustaining the momentum after returning to growth in the third quarter.

Integra (IART) Arms Grow Sequentially Despite Supply Issues

Integra LifeSciences (IART) is confident of achieving long-term goals of 5% to 7% revenue growth organically.

Integra (IART) Q4 Earnings Top Estimates, Revenues Fall Y/Y

Integra (IART) fourth-quarter 2020 revenues fell 1.6% year over year to $388.6 million but rose 5% sequentially.

Integra LifeSciences (IART) Surpasses Q4 Earnings and Revenue Estimates

Integra (IART) delivered earnings and revenue surprises of 13.51% and 0.29%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Veeva (VEEV) Partners With Impel, Boosts Cloud-Based Offerings

Veeva (VEEV) collaborates with Impel to accelerate the pre-launch planning and digital-first commercial execution for migraine treatment.

Integra (IART) Acquires Acell, Focuses on Regenerative Space

The acquisition is expected to remain accretive to Integra's (IART) revenue growth and adjusted gross margins.

Integra (IART) Preliminary Q4 Reported Sales Show Recovery

Integra's (IART) sales improvement in the fourth quarter is likely to have been boosted by on-going business recovery.

NEOGEN (NEOG) Fortifies Global Position via Megazyme Buyout

NEOGEN's (NEOG) buyout of Megazyme is expected to strengthen its Food Safety business worldwide.